These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 4459505)
41. [Evaluation of rubella vaccine (HPV 77, DK 12) in Mexico City. Possible transmission of its viral strain]. Ruíz-Gomez J; Gutiérrez G; Velasco-Cándano LR Arch Invest Med (Mex); 1971; 2(2):95-102. PubMed ID: 5136438 [No Abstract] [Full Text] [Related]
42. [Evaluation of rubella vaccine (HPV 77, DK12) in Mexico City. (Possible transmission of the vaccine strain)]. Ruíz-Gomez J; Gutiérrez G; Velasco-Cándano LR Arch Invest Med (Mex); 1971; 2(2):95-102. PubMed ID: 5116025 [No Abstract] [Full Text] [Related]
43. [Clinical test of an anti-rubella vaccine on a group of children belonging to a closed community]. Gasparini V; Trivello R; Diana L; Romano M; Drago E; Rausa G Minerva Med; 1970 Apr; 61(30 Suppl):1583-9. PubMed ID: 5439723 [No Abstract] [Full Text] [Related]
44. Persistence of antibody 10 years after vaccination with Wistar RA27/3 strain live attenuated rubella vaccine. Hillary IB; Griffith AH Br Med J; 1980 Jun; 280(6231):1580-1. PubMed ID: 7427177 [No Abstract] [Full Text] [Related]
45. Persistence of rubella antibodies 15 years after subcutaneous administration of Wistar 27/3 strain live attenuated rubella virus vaccine. Hillary IB; Griffith AH Vaccine; 1984 Dec; 2(4):274-6. PubMed ID: 6531967 [TBL] [Abstract][Full Text] [Related]
46. Attenuated rubella virus. II. Production of an experimental live-virus vaccine and clinical trial. Meyer HM; Parkman PD; Panos TC N Engl J Med; 1966 Sep; 275(11):575-80. PubMed ID: 5331945 [No Abstract] [Full Text] [Related]
47. Rubella antibody screening. Lang DJ J Fam Pract; 1978 Oct; 7(4):676-8. PubMed ID: 702068 [No Abstract] [Full Text] [Related]
48. Evaluation of the thermal stability of live-attenuated Rubella vaccine (Takahashi strain) formulated and lyophilized in different stabilizers. Shokri S; Shahkarami MK; Shafyi A; Mohammadi A; Esna-Ashari F; Hamta A J Virol Methods; 2019 Feb; 264():18-22. PubMed ID: 30144493 [TBL] [Abstract][Full Text] [Related]
49. Development of attenuated rubella virus vaccines in Japan. Shishido A; Ohtawara M Jpn J Med Sci Biol; 1976 Oct; 29(5):227-53. PubMed ID: 827627 [No Abstract] [Full Text] [Related]
50. [Variation of antibody titers following rubella immunization]. Sawada K; Sunaga H Nihon Eiseigaku Zasshi; 1975 Apr; 30(1):223. PubMed ID: 1169551 [No Abstract] [Full Text] [Related]
51. Live attenuated rubella virus vaccine: comparison of responses to HPV-77-DE5 and RA 27/3 strains. Gershon AA; Frey HM; Borkowsky W; Steinberg S Am J Med Sci; 1980; 279(2):95-7. PubMed ID: 7386521 [TBL] [Abstract][Full Text] [Related]
57. [Vaccination with live, non-virulent Trypanosoma cruzi vaccine in man. A 5-year follow up study the 1st 2 cases]. Menezes H AMB Rev Assoc Med Bras; 1976 Jul; 22(7):252-2. PubMed ID: 790483 [No Abstract] [Full Text] [Related]
58. Diffuse myelitis associated with rubella vaccination. Holt S; Hudgins D; Krishnan KR; Critchley EM Br Med J; 1976 Oct; 2(6043):1037-8. PubMed ID: 990751 [TBL] [Abstract][Full Text] [Related]
59. Production of vaccines with special reference to rubella vaccine RA 27-3 strain in WI 38 cells. Beale AJ Adv Exp Med Biol; 1972; 31(0):179-86. PubMed ID: 4671959 [No Abstract] [Full Text] [Related]
60. Serological follow-up after rubella immunisation. Ehrengut W; Lennartz H Br Med J; 1977 Aug; 2(6083):389. PubMed ID: 890315 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]